Laura L. Rokosz - Concepedia

Author

Laura L. Rokosz

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

L.L. Rokosz, Laura L Rokosz, Laura L. Rokosz, Laura Rokosz

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Pharmacopeial Convention WuXi AppTec (China)American Pharmacists Association United States Military Academy

About

Laura L. Rokosz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	528
2	Biochemistry	10	11	358
3	Natural Sciences	9	9	327
4	Health Sciences	2	2	39
5	Biomolecular Engineering	1	1	28

Laura L. Rokosz

Publications

956

Citations

H-Index

Page 1

	Year	Citations
Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme Joseph W. Becker, Alice I. Marcy, Laura L. Rokosz, Protein Science	1995	292
Discovery of 2-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist Michael P. Dwyer, Younong Yu, Jianping Chao, Journal of Medicinal Chemistry Pharmaceutical ScienceDrug TargetImmunologyPharmacotherapyLead Cyclobutenedione 3	2006	113
Regulation of calcineurin phosphatase activity and interaction with the FK-506.FK-506 binding protein complex. Janey N. Parsons, Greg Wiederrecht, Scott P. Salowe, Journal of Biological Chemistry	1994	63
Human Cytoplasmic 3-Hydroxy-3-methylglutaryl Coenzyme A Synthase: Expression, Purification, and Characterization of Recombinant Wild-Type and Cys129 Mutant Enzymes Laura L. Rokosz, David A. Boulton, E.A. Butkiewicz, Archives of Biochemistry and Biophysics BiosynthesisCellular EnzymologyBiochemistryNatural SciencesProtein Biosynthesis	1994	56
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms Ling Tong, Wensheng Yu, Lei Chen, Journal of Medicinal Chemistry Medicinal ChemistryAntiviral CompoundMolecular VirologyMedicineOptimized Activity	2016	47
Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists J. Robert Merritt, Laura L. Rokosz, Kingsley H. Nelson, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryMedicineCxcr2 AntagonistsHeterocycle Chemistry	2006	46
Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as γ-secretase inhibitors Tao Guo, Huizhong Gu, Doug W. Hobbs, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryNatural SciencesMedicinePyrrolidine Sulfonamide	2007	37
Surfing the piperazine core of tricyclic farnesyltransferase inhibitors Laura L. Rokosz, Chia-Yu Huang, John Reader, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryHeterocyclicBiochemistryNatural SciencesMedicine	2005	33
Synthesis of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A2A receptor antagonists Andrew G. Cole, Tara M. Stauffer, Laura L. Rokosz, Bioorganic & Medicinal Chemistry Letters MedicinePharmacological AgentPharmacotherapyPharmacologyMolecular Modeling	2008	30
Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists Yuefei Shao, Andrew G. Cole, Marc‐Raleigh Brescia, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryMedicineReceptor (Biochemistry)Trisubstituted Purinones	2009	29

Page 1